Kano Therapeutics

Circular single-stranded DNA templates: high-fidelity, immune-quiet, scalable.

health AI/biotech medtechgene therapy

Visit website LinkedIn ↗

StageSeed

Raised$7.1M to $7.44M

Founded2021

Employees12

LocationCambridge, MA

Business modelB2B, SaaS-like platform and partnership model (integrated DNA supply from discovery through GMP)

About

Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them.

Product

Value proposition: Kano provides circular single-stranded DNA (cssDNA) as a versatile, scalable genetic payload platform for cell and gene therapy, enabling precise editing, superior persistence, in vivo safety, and compatibility across delivery modalities and therapeutic approaches.
Target customers: biopharma and cell/gene therapy developers seeking dna payloads and integrated supply

Founders

Floris Engelhardt — Co-founder, CEO
John Vroom — Co-founder
Mark Bathe — Co-founder, Professor of biological engineering

Products

cssDNA (circular single-stranded DNA) platformDNA payloads for gene therapyKanoDNA payload platformpartnered DNA supply and integration solutions

Key features

Circular ssDNA payloadshigh-fidelity editing templatesimmune-quiet topologyscalable fermentation-based productionintegration across discovery to GMPone integrated partnership for DNA supply

Technologies

circular ssDNA (cssDNA)fermentation-based manufacturingsite-specific genome editingCRISPR/nuclease compatibilityrecombinase/transposon toolsnon-integrating DNA templates

Integrations

EHR integrations are not applicableplatform integrations with therapeutic pipelines (discovery to GMP)

Target conditions

Gene therapiesCAR-Tgenetic disease therapiesgenome editing applications

Care settings

research laboratoryclinical developmentGMP manufacturing environments

Partnerships

Integrated DNA payload platform partnershipsevaluation agreements leading to full partnerships

Traction metrics

Massachusetts Manufacturing Innovation Initiative (M2I2) grant recipient

Competitors

other DNA payload providers and gene editing platforms (not listed)

Investors

Engine VenturesVsquared VenturesMetaplanetTaihill VentureZAKA VenturesLaunchpad Venture GroupTermeer InstituteAcre Venture PartnersBIG Idea VenturesPrelude VenturesRefactor CapitalSOSV

News

A better DNA material for genetic medicine | MIT News · 2025-12-12T00:00:00.000Z
Kano Therapeutics: Funding, Team & Investors | Startup Intros · 2026-04-16T00:00:00.000Z
Kano Therapeutics 2026 Company Profile - PitchBook · 2024-08-12T00:00:00.000Z
Kano Therapeutics Secures $7.1M to Bring Targeted, Non-Viral DNA Insertion Technology to Genetic Medicine · 2024-08-12T00:00:00.000Z
Exclusive: MIT spinout launches with focus on improving DNA ... · 2024-08-09T00:00:00.000Z

Browse similar startups

Related startups

KINISI Physical Therapy & Sports Performance — Littleton, MA
Liberate Bio — Boston, MA
MelliCell, Inc. — Watertown, MA
Melorix Medical™ — Boston, MA
Mendhai Health — Cambridge, MA
MIND AND BODY BEHAVIORAL HEALTH CENTER — Canton, MA
Kardiolytics Inc. — Chicago, IL
Kedara.care — San Francisco, CA
Keensight Health — Bellevue, WA
Keeper Care — Seattle, WA
Kenko — Los Angeles, CA
Kennar Health — Hicksville, NY

Profile updated Jul 29, 2026. Sources: kanotherapeutics.com